Biogen Idec Oral MS Agent BG-12 Safety Takes Center Stage At Firm’s R&D Day
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Biogen Idec highlighted the safety profile of its oral multiple sclerosis compound BG-12 during its recent R&D Day.